| Igor Inoyatov, MD | |
|
1300 Franklin Ave Ste Ml6, Garden City, NY 11530-1760 | |
| (516) 535-1905 | |
| Not Available |
| Full Name | Igor Inoyatov |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 1300 Franklin Ave Ste Ml6, Garden City, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205368248 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 315711 (New York) | Primary |
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20081202000185 |
News Archive
Survival rates of childhood cancers, especially leukemia, have improved greatly in the past three decades, but survivors of this disease still seem to face many health and lifestyle challenges as young adults.
Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.
Breast cancer survivors with poor physical health scores had an elevated risk of poorer cancer outcomes, including recurrence and death, according to the results of an observational study presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
World leading scientists are to be targeted by Cancer Research UK and its development and commercialisation arm Cancer Research Technology (CRT), in an effort to tackle some of cancer's most pressing scientific challenges.
› Verified 6 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
Survival rates of childhood cancers, especially leukemia, have improved greatly in the past three decades, but survivors of this disease still seem to face many health and lifestyle challenges as young adults.
Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.
Breast cancer survivors with poor physical health scores had an elevated risk of poorer cancer outcomes, including recurrence and death, according to the results of an observational study presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
World leading scientists are to be targeted by Cancer Research UK and its development and commercialisation arm Cancer Research Technology (CRT), in an effort to tackle some of cancer's most pressing scientific challenges.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Igor Inoyatov, MD 58-35 256th Street, Little Neck, New York, NY 11362 Ph: () - | Igor Inoyatov, MD 1300 Franklin Ave Ste Ml6, Garden City, NY 11530-1760 Ph: (516) 535-1905 |
News Archive
Survival rates of childhood cancers, especially leukemia, have improved greatly in the past three decades, but survivors of this disease still seem to face many health and lifestyle challenges as young adults.
Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.
Breast cancer survivors with poor physical health scores had an elevated risk of poorer cancer outcomes, including recurrence and death, according to the results of an observational study presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
World leading scientists are to be targeted by Cancer Research UK and its development and commercialisation arm Cancer Research Technology (CRT), in an effort to tackle some of cancer's most pressing scientific challenges.
› Verified 6 days ago
Jeffrey H Lumerman, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 601 Franklin Ave, Suite 300, Garden City, NY 11530 Phone: 516-742-3200 Fax: 516-746-5847 | |
Dr. Omid Rofeim, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 233 7th St, Suite 203, Garden City, NY 11530 Phone: 516-294-7666 Fax: 516-294-7672 | |
Barry R Shepard, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 601 Franklin Ave, Suite 300, Garden City, NY 11530 Phone: 516-742-3200 Fax: 516-746-5847 | |
Brett C Mellinger, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 100 Garden City Plaza, Suite 102, Garden City, NY 11530 Phone: 516-873-5353 Fax: 516-873-8850 | |
Mitchell D Efros, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1305 Franklin Ave, Garden City, NY 11530 Phone: 516-742-3200 Fax: 516-746-5847 | |
Anthony M Bruno, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1305 Franklin Ave, Suite 100, Garden City, NY 11530 Phone: 516-746-5550 Fax: 516-746-9641 |